2021
DOI: 10.1021/acsami.1c07821
|View full text |Cite
|
Sign up to set email alerts
|

“Plug and Play” Functionalized Erythrocyte Nanoplatform for Target Atherosclerosis Management

Abstract: For atherosclerosis (AS) management, a therapeutic drug intervention is the most widely used strategy. However, there are some problems such as low location specificity, high intake, and side effects. Nanomedicine can prolong the half-life of drug solubilization, reduce toxic and side effects, and improve the distribution of drug objects. Herein, to overcome the challenges, an erythrocyte-based “plug and play” nanoplatform was developed by incorporating the vascular cell adhesion molecule-1 (VCAM-1) targeting … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
30
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 31 publications
(30 citation statements)
references
References 55 publications
0
30
0
Order By: Relevance
“… 199 Similar improved approach, applying the novel plug and play functionalized erythrocyte nanoplatform targeted drug delivery and acetic acid-control drug release show a marked improvement in atherosclerosis. 200 In addition, based on the inherent affinity of macrophages for atherosclerotic lesions to construct biomimetic NPs fabricated with a macrophage membrane coating on the surface of rapamycin-loaded poly copolymer NPs has been demonstrated to effectively inhibit the progression of atherosclerosis. 201 Although these findings suggest that using NPs to deliver anti-inflammatory substances is promising results, further basic research is necessary to understand more about the underlying functional mechanisms of the NPs.…”
Section: Signaling Pathways In Atherosclerosismentioning
confidence: 99%
“… 199 Similar improved approach, applying the novel plug and play functionalized erythrocyte nanoplatform targeted drug delivery and acetic acid-control drug release show a marked improvement in atherosclerosis. 200 In addition, based on the inherent affinity of macrophages for atherosclerotic lesions to construct biomimetic NPs fabricated with a macrophage membrane coating on the surface of rapamycin-loaded poly copolymer NPs has been demonstrated to effectively inhibit the progression of atherosclerosis. 201 Although these findings suggest that using NPs to deliver anti-inflammatory substances is promising results, further basic research is necessary to understand more about the underlying functional mechanisms of the NPs.…”
Section: Signaling Pathways In Atherosclerosismentioning
confidence: 99%
“…constructed a pH‐sensitive prodrug by binding docetaxel (DTX) with an acid‐cleavable ester bond ( Figure a). [ 121 ] The prodrug‐labeled erythrocyte nanoplatform (RBC@DTX/CR 8 ) controlled the activated DTX release in response to the acidic environment of plaque lesions (Figure 11b), achieving an efficient and safe therapy for atherosclerotic plaques. Dou et al.…”
Section: The Targeting Strategies For the Therapy Of Vulnerable Ather...mentioning
confidence: 99%
“…In the in vivo study, the plaque area ) Reproduced with permission. [121] Copyright 2021, American Chemical Society. c) Schematic representation of the pH-responsive RAP/Ac-bCD.…”
Section: Macrophage Depletion Therapymentioning
confidence: 99%
“…Accordingly, Wang's group fabricated a VHPKQHR peptide and docetaxel functionalized erythrocyte nanoplatform via phospholipid polymer phosphatidylethanolamine (DSPE)-PEG2000, which guaranteed a local drug release. 194 VECs, VSMCs and macrophages are closely related to the development of atherosclerosis and vascular restenosis, and thus the cell membranes of these cells have attracted interest. Inflammatory cells play a critical role in the processes of atherosclerosis.…”
Section: Biomimetic Membrane-coated Nanomaterialsmentioning
confidence: 99%